Literature DB >> 20595634

Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.

Yuenian Eric Shi1, Yiding Chen, Raduwan Dackour, Louis Potters, Shui Wang, Qiang Ding, Zhaoyi Wang, Yiliang Ellie Liu.   

Abstract

Synuclein gamma (SNCG), previously identified as a breast cancer-specific gene, is highly expressed in malignant cancer cells but not in normal epithelium. The molecular targets of SNCG during breast cancer progression have not been fully identified. Here we analyzed the effect of SNCG on stimulation of membrane-initiated estrogen signaling. While SNCG expression enhanced estrogen-induced activation of ERK1/2 and mammalian target of rapamycin, knockdown of endogenous SNCG decreased membrane-initiated estrogen signaling. SNCG functions as a molecular chaperone protein for estrogen receptor (ER)-alpha36, a membrane-based variant of ER-alpha. SNCG bound to ER-alpha36 in the presence and absence of functional molecular chaperone heat shock protein 90. Disruption of heat shock protein 90 with 17-AAG significantly reduced ER-alpha36 expression and membrane-initiated estrogen signaling. However, expression of SNCG prevented ER-alpha36 degradation and completely recovered 17-AAG-mediated down-regulation of estrogen signaling. The function of SNCG in ER-alpha36-mediated estrogen signaling is consistent with its ability to stimulate cell growth in response to estrogen. Expression of SNCG also renders tamoxifen resistance, which is consistent with the clinical observation on the association of ER-alpha36 expression and tamoxifen resistance. The present study indicates that ER-alpha36 is a new member of the ER-alpha family that mediates membrane-initiated estrogen signaling and that SNCG can replace the function of heat shock protein 90, chaperone ER-alpha36 activity, stimulate ligand-dependent cell growth, and render tamoxifen resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595634      PMCID: PMC2913349          DOI: 10.2353/ajpath.2010.100061

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

Review 1.  Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling.

Authors:  Paul H Driggers; James H Segars
Journal:  Trends Endocrinol Metab       Date:  2002-12       Impact factor: 12.015

2.  Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.

Authors:  Ariel F Castro; John F Rebhun; Geoffrey J Clark; Lawrence A Quilliam
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

3.  Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.

Authors:  Haiyan Liu; Wei Liu; Yinwei Wu; Yue Zhou; Rong Xue; Chan Luo; Lan Wang; Wei Zhao; Jian-Dong Jiang; Jingwen Liu
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 4.  Rapid actions of plasma membrane estrogen receptors.

Authors:  M J Kelly; E R Levin
Journal:  Trends Endocrinol Metab       Date:  2001 May-Jun       Impact factor: 12.015

5.  Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells.

Authors:  D C Márquez; R J Pietras
Journal:  Oncogene       Date:  2001-09-06       Impact factor: 9.867

6.  Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary.

Authors:  W Bruening; B I Giasson; A J Klein-Szanto; V M Lee; J Q Trojanowski; A K Godwin
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

7.  Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.

Authors:  David B Solit; Andrea D Basso; Adam B Olshen; Howard I Scher; Neal Rosen
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

8.  Stage-specific expression of breast cancer-specific gene gamma-synuclein.

Authors:  Kejin Wu; Ziyi Weng; Qinghua Tao; Gufa Lin; Xiangru Wu; Huiqin Qian; Yichu Zhang; Xiaoyan Ding; Yangfu Jiang; Yuenian Eric Shi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-09       Impact factor: 4.254

9.  Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1.

Authors:  Anu Gupta; Satoru Inaba; Oi Kwan Wong; Guowei Fang; Jingwen Liu
Journal:  Oncogene       Date:  2003-10-23       Impact factor: 9.867

10.  Stimulation of estrogen receptor signaling by gamma synuclein.

Authors:  Yangfu Jiang; Yiliang Ellie Liu; AiPing Lu; Anu Gupta; Itzhak D Goldberg; Jingwen Liu; Y Eric Shi
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

View more
  12 in total

1.  Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Abigail D Winder; Kruti P Maniar; Jian-Jun Wei; Dachao Liu; Denise M Scholtens; John R Lurain; Julian C Schink; Barbara M Buttin; Virginia L Filiaci; Heather A Lankes; Nilsa C Ramirez; Kay Park; Meenakshi Singh; Richard W Lieberman; Robert S Mannel; Matthew A Powell; Floor J Backes; Cara A Mathews; Michael L Pearl; Angeles Alvarez Secord; David J Peace; David G Mutch; William T Creasman; J Julie Kim
Journal:  Cancer       Date:  2016-12-07       Impact factor: 6.860

2.  Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption.

Authors:  Yongfeng Shao; Bingchan Wang; Dorothy Shi; Suyu Miao; Panneerselvam Manivel; Ramadas Krishna; Yiding Chen; Y Eric Shi
Journal:  Mol Oncol       Date:  2014-06-14       Impact factor: 6.603

3.  An exploratory analysis of γ-synuclein expression in endometrioid endometrial cancer.

Authors:  Jing Zou; Yujuan J Fan; Yaqing Q Meng; Hong Xu; Jiangtao Fan
Journal:  BMJ Open       Date:  2012-04-24       Impact factor: 2.692

Review 4.  Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Genet Epigenet       Date:  2015-12-02

5.  Chaperone gp96 mediates ER-α36 cell membrane expression.

Authors:  Junwei Hou; Mengmeng Deng; Xin Li; Weiwei Liu; Xiaoyu Chu; Jing Wang; Feng Chen; Songdong Meng
Journal:  Oncotarget       Date:  2015-10-13

6.  Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform.

Authors:  Kathrin Schaal; Marc Hirschfeld; Peter Bronsert; Hannah Füllgraf; Markus Jäger; Bettina Herde; Claudia Nöthling; Sebastian Mayer; Thalia Erbes; Elmar Stickeler
Journal:  Oncotarget       Date:  2015-09-08

7.  Cell-specific post-transcriptional regulation of γ-synuclein gene by micro-RNAs.

Authors:  Irina Surgucheva; Sumedha Gunewardena; H Shanker Rao; Andrei Surguchov
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

8.  GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.

Authors:  Zhiqiang Mo; Manran Liu; Fangfang Yang; Haojun Luo; Zhenhua Li; Gang Tu; Guanglun Yang
Journal:  Breast Cancer Res       Date:  2013-11-29       Impact factor: 6.466

Review 9.  ER-α36: a novel biomarker and potential therapeutic target in breast cancer.

Authors:  Xingyun Su; Xin Xu; Guangliang Li; Bingyi Lin; Jiang Cao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2014-08-30       Impact factor: 4.147

10.  Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.

Authors:  Caiyun Liu; Bingbing Shi; Chonghua Hao; Qinghai Wang; Qiang Lv; Nianzeng Xing; Jianzhong Shou; Like Qu; Yanning Gao; Chao Qin; Jiyu Zhao; Chengchao Shou
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.